Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Darlene Johnson

MOHS-Micrographic Surgery Aurora, CO Medical Doctor

NPI 1821080391 CMS profile 1013153

1390 S Potomac St, Suite 124, Aurora, CO 80012

Open in the dashboard

General payments

$3,694

178 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Darlene Johnson of Aurora, CO is reported in the CMS Open Payments database as having received $3,694 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $352 12
2024 General $943 29
2023 General $642 24
2022 General $492 23
2021 General $380 17
2020 General $365 30
2019 General $520 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darlene Johnson
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Darlene Johnson were reported at $352. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Darlene Johnson MOHS-Micrographic Surgery median Middle half National median
2019 $520 $316 $106–$785 $163
2020 $365 $162 $68–$412 $114
2021 $380 $243 $87–$654 $132
2022 $492 $300 $102–$887 $149
2023 $642 $364 $125–$1,010 $160
2024 $943 $445 $142–$1,108 $164
2025 $352 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $472 19 payments
  2. Genzyme Corporation $441 15 payments
  3. Lilly USA, LLC $385 11 payments
  4. Amgen Inc. $328 10 payments
  5. LEO Pharma Inc. $315 49 payments
  6. Sun Pharmaceutical Industries Inc. $267 8 payments
  7. Regeneron Healthcare Solutions, Inc. $262 9 payments
  8. Janssen Biotech, Inc. $241 14 payments
  9. Novartis Pharmaceuticals Corporation $179 10 payments
  10. E.R. Squibb & Sons, L.L.C. $144 6 payments
  11. Other $660 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,694 178 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $556 19 payments
  2. ENSTILAR $282 47 payments
  3. SKYRIZI $260 10 payments
  4. TREMFYA $226 13 payments
  5. Otezla $206 9 payments
  6. OLUMIANT $194 4 payments
  7. DUPIXENT Inflammation And Immunology $172 6 payments
  8. TALTZ $149 7 payments
  9. SOTYKTU $144 6 payments
  10. RINVOQ $135 6 payments
  11. Other $1,777 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

304

Median for Dermatology: 534

Drug cost

$3,762

Median for Dermatology: $67,151

Branded share of claims

6.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mupirocin Generic 95 $891
Doxycycline Monohydrate Generic 75 $861
Minoxidil Generic 35 $518
Imiquimod Generic 11 $413
Valacyclovir Valacyclovir Hcl Brand 21 $386
Fluconazole Generic 11 $244
Triamcinolone Acetonide Generic 12 $154
Cephalexin Generic 31 $147
Doxycycline Hyclate Generic 13 $147

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 97 billing codes

Paid by Medicare

$272,887

Of which drugs: $55

Medicare patients

437

Average age 76

Services billed

2,140

199 women, 238 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 41%
Ischemic heart disease 19%
Chronic kidney disease 19%
Cancer 17%
Depression 16%
Osteoporosis 16%
Diabetes 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 27 46 $35

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $274
  • Regeneron Healthcare Solutions, Inc. $123
$397 — —
OLUMIANT
  • Lilly USA, LLC $121
$121 — —
VTAMA
  • Dermavant Sciences, Inc. $118
$118 — —
Otezla
  • Amgen Inc. $96
$96 — —
RINVOQ
  • AbbVie, Inc. $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record